Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

(2015) D. Cardinale et al.   CIRCULATION

Cancer treatment and survivorship statistics, 2014

(2014) Carol E. DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction

(2014) Carlo G. Tocchetti et al.   EUROPEAN JOURNAL OF HEART FAILURE

Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer

(2014) Giulia Russo et al.   Journal of Cardiovascular Medicine

Prevention of Anthracycline-Induced Cardiotoxicity

(2014) Pimprapa Vejpongsa et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

(2014) Ghideon Ezaz et al.   Journal of the American Heart Association

The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors

(2013) Carlo G. Tocchetti et al.   EUROPEAN JOURNAL OF HEART FAILURE

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade

(2013) Antonis Valachis et al.   INTERNATIONAL JOURNAL OF CANCER

Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice

(2013) M. Khair ElZarrad et al.   PLoS One

Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis

(2012) L. Tarantini et al.   ANNALS OF ONCOLOGY

Mechanisms of cardiotoxicity associated with ErbB2 inhibitors

(2012) Carmine Fedele et al.   BREAST CANCER RESEARCH AND TREATMENT

Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab

(2012) Heloisa Sawaya et al.   Circulation-Cardiovascular Imaging

Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge

(2012) Carlo G. Tocchetti et al.   EUROPEAN JOURNAL OF HEART FAILURE

Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

(2012) Jersey Chen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study

(2012) E. J. A. Bowles et al.   JNCI-Journal of the National Cancer Institute

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

Administration of Angiotensin-Converting Enzyme Inhibitors and  -Blockers During Adjuvant Trastuzumab Chemotherapy for Nonmetastatic Breast Cancer: Marker of Risk or Cardioprotection in the Real World?

(2012) S. Oliva et al.   ONCOLOGIST

Cardiac-Specific Over-Expression of Epidermal Growth Factor Receptor 2 (ErbB2) Induces Pro-Survival Pathways and Hypertrophic Cardiomyopathy in Mice

(2012) Polina Sysa-Shah et al.   PLoS One

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors

(2011) C. Serrano et al.   ANNALS OF ONCOLOGY

Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors

(2011) Carmine Fedele et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer

(2011) Luigi Tarantini et al.   JOURNAL OF CARDIAC FAILURE

The Cardioprotective Role of Probucol Against Anthracycline and Trastuzumab-Mediated Cardiotoxicity

(2011) Jonathan R. Walker et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Vulnerability of the Heart As a Pluricellular Paracrine Organ

(2010) Gilles W. De Keulenaer et al.   CIRCULATION RESEARCH

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

(2010) Thomas Eschenhagen et al.   EUROPEAN JOURNAL OF HEART FAILURE

Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy

(2010) Nicola Maurea et al.   Journal of Cardiovascular Medicine

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

(2010) Michael S. Ewer et al.   Nature Reviews Cardiology

Reversibility of Left Ventricular Dysfunction Resulting from Chemotherapy: Can This Be Expected?

(2010) Quinn S. Wells et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury

(2009) Kevin Bersell et al.   CELL

Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents

(2009) Gennaro Riccio et al.   FASEB JOURNAL

Utility of Tissue Doppler and Strain Rate Imaging in the Early Detection of Trastuzumab and Anthracycline Mediated Cardiomyopathy

(2009) Davinder S. Jassal et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Cardiotoxicity Profile of Trastuzumab

(2008) Steven M Ewer et al.   DRUG SAFETY

Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways

(2008) Leo I. Gordon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY